Core Viewpoint - The article discusses the challenges and reforms in transforming the vast untapped intangible assets of public hospitals in China, particularly focusing on Shanghai's initiatives to enhance the conversion rate of medical research outcomes, which currently stands at a mere 8% compared to developed countries. Group 1: Challenges in Technology Transfer - China's medical technology conversion rate is below 8%, indicating a structural dilemma of "rich in research but poor in conversion" [2] - Public hospital patents are classified as state-owned assets, complicating the evaluation, pricing, and transfer processes, leading to inefficiencies and fears of asset loss [2][10] - The traditional process involves extensive bureaucratic hurdles, often taking over a year for a single patent transfer due to the need for multiple departmental approvals [2][3] Group 2: Shanghai's Reform Initiatives - Shanghai is implementing reforms to decentralize the rights to use, dispose of, and benefit from scientific achievements, aiming to break the conversion rate "curse" [1][2] - In 2022, Shanghai introduced operational guidelines to promote the conversion of scientific achievements in medical institutions, with 17 hospitals participating in pilot programs [2][12] - The introduction of "rights confirmation" and "due diligence exemption" is seen as key to overcoming existing barriers [2] Group 3: Successful Case Studies - Renji Hospital has seen a 575% increase in project numbers and a 210% increase in contract amounts since implementing a pilot program for managing scientific achievements [3] - Ruijin Hospital has developed a comprehensive service ecosystem for technology transfer, including a policy that allocates 80% of net conversion profits to research teams, addressing motivation issues among doctors [5][10] - Zhongshan Hospital has adopted a flexible pricing model that allows direct negotiations between inventors and companies, significantly reducing the time from rights confirmation to contract signing to just two months [8][9] Group 4: Future Prospects and Industry Support - The Shanghai government is actively supporting the biopharmaceutical industry with policies aimed at enhancing the entire innovation chain, from research to commercialization [12][13] - The establishment of the Guangci-Sinan National Translational Medicine Innovation Industrial Park is attracting numerous companies, with 283 companies and a registered capital of approximately 2.9 billion yuan by 2025 [7] - The Shanghai Children's Medical Center is set to launch a nationwide conversion project for a self-developed diagnostic kit, marking a significant step towards industrialization [10][11]

Core Insights - The article highlights the transformation and innovation journey of the Henan Daily, focusing on its upgraded version that aims to capture and report on the dynamic innovation landscape in Henan province [1][2] Group 1: Innovation Tracking - The publication has been actively tracking and documenting the most vibrant "energy signals" of innovation in Henan, providing a snapshot of ongoing developments [1] - It emphasizes the importance of new policies in igniting innovation and setting rules for emerging sectors, showcasing the interaction between research and practical application [1][5] - The "Technology Vice President" initiative has been launched, facilitating collaboration between academic institutions and enterprises to address technological challenges [5][7] Group 2: Policy Interpretation - The article discusses the timely interpretation of significant policy documents related to technological innovation, aiming to uncover development opportunities and actionable paths [5][7] - It notes that the innovation policies in Henan are evolving to create a collaborative environment where academia and industry can work together effectively [7][8] Group 3: Innovation Highlights - Key innovations include humanoid robots showcased at the Central Henan Intelligent Laboratory and advancements in agricultural technology, such as high-yield corn varieties [9][10] - The establishment of the world's first nanoenzyme pilot production line marks a significant step towards industrialization of cutting-edge technologies [10] - The article captures the essence of Henan's growing technological capabilities and the emergence of new industrial chains [10][11] Group 4: Celebrating Innovators - The narrative honors key figures in Henan's innovation landscape, such as agricultural scientists who have made significant contributions to crop breeding [11][15] - It reflects on the societal respect for scientists and the importance of fostering a culture that values knowledge and innovation [13][15]

Group 1: Medical Innovations - The Henan Health Industry Development Conference showcased several medical research achievements, including an ex vivo heart transport system and a precision massage robot, indicating a shift from theoretical concepts to practical applications in the medical field [1] - The Central Plains Nanozyme Laboratory is developing rapid test strips for various infectious diseases, with expected annual output exceeding 100 million yuan after market launch, and plans to establish a straw degradation base with an annual capacity of 500,000 tons [2] - The Fuxi AI model, developed by a team led by an academician, has upgraded to version 2.0, featuring the largest dataset globally for ophthalmology AI, and is being piloted in 11 hospitals across four provinces [3] Group 2: Organ Transplant and Precision Medicine - A breakthrough ex vivo heart transport system has been developed, allowing for the preservation of a heart for over 24 hours, which is crucial for organ transplantation [4] - A "chip factory" is being established to produce micro copies of human organs using AI and organ-on-a-chip technology, with a projected annual capacity of 10,000 chips upon completion in 2026 [5] Group 3: AI and Traditional Medicine Integration - The establishment of a national AI application pilot base focused on integrating AI with traditional Chinese medicine aims to create a public platform for standardized development in the industry, offering various core services [6] - The pilot base has signed agreements with 13 ecological partners to promote the application of AI in auxiliary diagnosis and health management, enhancing the efficiency of grassroots medical services [7]

Core Insights - The 2025 Wu Jieping Medical Award and Wu Jieping Medical Innovation Award were recently presented, recognizing significant contributions in the medical field [1][2] - Notable winners include Professor Hao Xishan, an expert in oncology, and Professor Xie Lixin, an expert in ophthalmology, both of whom have made groundbreaking advancements in their respective fields [1][2] Group 1: Award Winners and Contributions - Professor Hao Xishan has dedicated over 50 years to oncology, achieving innovative results in tumor surgery, immunotherapy, and epidemiology. He pioneered the "functional interposition jejunal gastric replacement" surgery for gastric cancer, significantly improving patient quality of life and survival rates [1] - Professor Xie Lixin has focused on corneal diseases and cataract research, proposing new theories for corneal endothelial cell function assessment and conducting the first epidemiological survey of corneal diseases in China. He has developed several products to address corneal donor shortages [2] Group 2: Recognition and Future Goals - Both awardees expressed gratitude for the recognition, emphasizing the importance of their teams and the broader implications for China's medical innovation [2][3] - The Wu Jieping Medical Award evaluation committee, led by academician Han Qide, highlighted the awards' significance in improving the medical evaluation system in China and the need for ongoing efforts to enhance the awards' impact and recognition [3]

Core Viewpoint - The Decheng District Traditional Chinese Medicine Hospital (Dezhou United Hospital) has achieved a significant milestone by having its first research paper accepted in the SCI journal, marking a breakthrough in high-level academic research for the institution [1][6][13]. Group 1: Research Achievement - The paper titled "Follicular Dendritic Cell Sarcoma in Mediastinum: A Case Study and Literature Review" was authored by Dr. Ma Yang and his team, highlighting the hospital's capabilities in addressing rare and challenging clinical conditions [1][6]. - This research focuses on follicular dendritic cell sarcoma (FDCS), a rare malignancy, and provides valuable insights into its clinical diagnosis and treatment through a detailed case analysis and literature review [6][9]. Group 2: Research Process and Contributions - The research was initiated at the end of 2023 and involved nearly two years of effort from Dr. Ma Yang's team, showcasing their dedication and expertise in the field [6][9]. - Dr. Ma Yang served as both the co-first author and corresponding author, demonstrating his leadership and academic influence within the hospital [9]. Group 3: Institutional Support and Future Directions - The hospital emphasizes talent development and research innovation, actively encouraging medical staff to engage in academic research and improving research funding and evaluation mechanisms [9][13]. - The success of this paper reflects the hospital's commitment to a collaborative development strategy in medicine, education, and research, laying a solid foundation for future high-quality research output and enhancing the hospital's academic reputation [9][13].

Core Viewpoint - The 2025 Wu Jieping Medical Award and Wu Jieping Medical Innovation Award ceremony was held at Capital Medical University, celebrating significant contributions to the medical field in China and honoring the legacy of Wu Jieping [1][3][4]. Group 1: Award Ceremony Highlights - The ceremony featured over 600 attendees, including prominent figures in the medical field, who gathered to honor the achievements of award recipients and reflect on the values embodied by Wu Jieping [1][3]. - A commemorative video highlighted Wu Jieping's dedication to medicine and patient care, emphasizing his spirit of "helping the injured and respecting virtue" [3]. - The event marked the 65th anniversary of Capital Medical University, which has trained over 100,000 medical professionals, contributing significantly to China's healthcare development [4]. Group 2: Award Recipients - The 2025 Wu Jieping Medical Award was awarded to: - Professor Hao Xishan, an expert in oncology, recognized for his innovative contributions to cancer treatment and research, including the development of a groundbreaking surgical technique for gastric cancer [5][6]. - Professor Xie Lixin, an ophthalmology expert, acknowledged for his advancements in corneal disease treatment and cataract surgery, significantly impacting patient care in China [6][7]. - The 2025 Wu Jieping Medical Innovation Award recipients included: - Professor Bu Jun, a cardiovascular expert, noted for his work in early prevention and precision treatment of cardiovascular diseases, contributing to international medical standards [7][8]. - Professor Wang Zhining, recognized for his research in gastrointestinal cancer, developing new diagnostic and treatment methods [8][9]. - Professor Liu Zhang, who made significant contributions to the understanding and treatment of chronic sinusitis and allergic rhinitis [9]. - Professor Tang Yi, who developed digital diagnostic strategies for cognitive disorders, impacting over 20 million patients [9][10]. - Professor Cui Yimin, who has led numerous clinical trials and contributed to the development of innovative drugs in China [10]. Group 3: Future Directions and Impact - The Wu Jieping Medical Foundation plans to establish the "Wu Jieping Outstanding Graduate Award" to inspire future medical professionals to uphold high ethical standards and dedication to patient care [4]. - The ceremony concluded with a call to continue promoting the values of Wu Jieping, encouraging medical professionals to innovate and contribute to the health of the nation [11].

Core Insights - The Chinese Academy of Medical Sciences has announced procurement intentions for 19 items of medical equipment, with a total budget of 98.25 million yuan [1][2]. Procurement Overview - The procurement includes various advanced medical instruments such as: - Fully automated chemiluminescence analyzers - Fully automated sample processing systems - Triple quadrupole liquid chromatography-mass spectrometry systems - Traditional flow cytometers - Single-cell suspension preparation systems - Hypoxia workstations - Real-time high-throughput spectral analysis systems - Surface plasmon resonance molecular interaction analyzers - High-speed refrigerated centrifuges [2][3]. Detailed Procurement List - Specific items and their budgets include: - Flat-panel microscope: 650,000 yuan - Digital slide scanning system: 195,000 yuan - Cryostat: 250,000 yuan - Multifunctional imaging system: 500,000 yuan - Fully automated mass spectrometer: 180,000 yuan - Research-grade single-channel automated patch clamp system: 150,000 yuan - Two-photon confocal microscope: 500,000 yuan - Fully automated blood dispensing workstation: 165,000 yuan - Triple quadrupole liquid chromatography-mass spectrometry system: 400,000 yuan - Total budget for the procurement is 98.25 million yuan, with expected procurement time from September to December 2025 [3][5][6].

Group 1 - The main structure of the Translational Medicine Building at Tongji Hospital has been completed and is now entering the decoration and electromechanical installation phase, expected to be operational by the end of 2026, housing high-level research platforms including a brain-computer interface research center [1] - Six projects from Chu merchants, including Baicao Jishi and Maikesen headquarters, have signed agreements with a total investment of 5.5 billion yuan during the National Day and Mid-Autumn Festival forum [1] Group 2 - The Sino-French Ecological City has been developing since 2014, covering an area of 39 square kilometers, and has attracted 30 headquarters economic projects [2] Group 3 - The Kaiyuan Senbo Resort Park achieved over 100 million yuan in pre-sales within 10 days [3] Group 4 - Zhongjian Green Creation Company has developed the world's first intelligent, unmanned production line for building curtain wall processing, with a production value exceeding 1 billion yuan, and aims to become an "invisible champion" in the industry [4] - The ecological buffer zone near the company, covering approximately 62.2 hectares, features a "U"-shaped design with interconnected ponds and a rich ecosystem [4] - The Kaiyuan Senbo Resort Park, which opened in June, has quickly gained recognition, ranking 58th among Asia's top 100 family-friendly resort hotels [4] - The management of the Sino-French Ecological City is actively exploring the transformation of ecological value into cultural tourism products, with projects like the Huazhong Aerospace Museum and high-end homestays under construction [4]

Core Viewpoint - The Ministry of Science and Technology has announced the approval of a key project under the 2025 National Key R&D Program focused on "Diagnostic Equipment and Biomedical Materials," led by Professor Ni Xinye from the Third Affiliated Hospital of Nanjing Medical University, addressing critical challenges in real-time dose verification in radiation therapy [1][2]. Group 1: Project Details - The approved project is the first National Key R&D Program project in Jiangsu's radiation therapy sector, with a project leader from the Changzhou health system [1]. - The project aims to tackle the "bottleneck" issue of in-vivo dose verification in radiation therapy by integrating resources from universities, hospitals, and leading enterprises, establishing a collaborative innovation mechanism [1]. Group 2: Impact and Significance - The research outcomes are expected to provide crucial support for clinical translation and industrial upgrading in cutting-edge fields like real-time adaptive radiotherapy, contributing significantly to the implementation of the "Healthy China" strategy [1]. - The project will enhance the precision and safety of treatment for radiation therapy patients, facilitating a transition in China's radiation therapy from "planned precision" to "execution precision" [1].

当日，一批院士合作平台正式揭牌：中国—东盟医疗保健合作中心（广西）广西医科大学第一附属 医院代谢与健康广西院士工作站将立足广西区域高发肿瘤（如肝癌、鼻咽癌）防治的重大需求，致力于 推动代谢调控前沿理论与广西特色临床资源的深度融合；广西零磁肿瘤医学重点实验室将系统开展超高 灵敏极弱磁测量技术研究，突破肿瘤早期、精准、无创功能性疗效评估等关键技术瓶颈，结合人工智能 技术开发智能诊断模型，建立具有自主知识产权的技术装备与诊疗方案等；广西壮族自治区人民医院 （广西医学科学院）器官移植医学中心揭牌后，将聚焦临床移植创新与转化、基础与转化医学、器官捐 献与伦理医学、数据与人工智能、培训与国际交流等五大研究方向，攻克器官移植领域的重大理论和技 术瓶颈，为终末期器官衰竭患者提供更先进、更系统的诊疗服务。 同时揭牌的还有中山大学研究生培养基地（广西少数民族高层次骨干人才计划）、柯麟医学人文学 院（广西分院）、中山大学附属第一医院显微外科机器人（广西）培训中心。会上还举行了院士与广西 医学高校、医院及东盟国家相关院校共建项目的签约仪式，合作范围涵盖国际药学、现代医药科技创业 园建设、中药无抗养殖技术等领域。 11月29日，由11 ...